MORE►
neurological disorders
[Source image: istockphoto]
Taysha Gene Therapies Raises $150M for Its Rare Disease Drug Pipeline
by Lance Murray | Aug 16, 2023
Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.
by Lance Murray |
Jun 16, 2023
In a pivotal year, which saw Reata Pharmaceuticals halt research for a kidney disease treatment and receive FDA approval for its first-to-market degenerative disease treatment, the company welcomes Dr. Rajiv Patni as Chief R&D Officer. Patni marks this as an "inflection point to become a global, commercial-stage company with an expanding pipeline in both rare and common serious diseases."
MORE►
by Lance Murray |
May 25, 2018
Plus, researchers may have found a common link between four neurological conditions. Find out more in the weekly roundup of research and development in Dallas-Fort Worth.
MORE►
